Diminished WNT → β-catenin → c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors

Genes and Development

Volumn 28, Issue 6, 2014, Pages 561-575

  Juan, Joseph ^a,b   Muraguchi, Teruyuki ^a,b,d   Iezza, Gioia ^b   Sears, Rosalie C ^c   McMahon, Martin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

BRAF; c MYC; Non small cell lung cancer; catenin

Indexed keywords

ACYLTRANSFERASE; B RAF KINASE; BETA CATENIN; MYC PROTEIN; PORCUPINE ACYLTRANSFERASE; UNCLASSIFIED DRUG; WNT PROTEIN; BRAF PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B RAF KINASE GENE; CONTROLLED STUDY; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; LUNG CARCINOGENESIS; LUNG PARENCHYMA; LUNG TUMOR; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE INDUCED SENESCENCE; PORCUPINE; PRIORITY JOURNAL; PROTEIN SECRETION; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; WNT SIGNALING PATHWAY; ANIMAL; BRAF; C-MYC; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NON-SMALL-CELL LUNG CANCER; PATHOPHYSIOLOGY; Β-CATENIN;

BRAF; C-MYC; NON-SMALL-CELL LUNG CANCER; Β-CATENIN;

ANIMALS; BETA CATENIN; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; LUNG NEOPLASMS; MICE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84896358575     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.233627.113     Document Type: Article

References (66)

1. Ashton GH, Morton JP, Myant K, Phesse TJ, Ridgway RA, Marsh V, Wilkins JA, Athineos D, Muncan V, Kemp R, et al. 2010. Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev Cell 19: 259-269.
2. Aziz N, Cherwinski H, McMahon M. 1999. Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src. Mol Cell Biol 19: 1101-1115.
3. Beers MF, Morrisey EE. 2011. The three R's of lung health and disease: Repair, remodeling, and regeneration. J Clin Invest 121: 2065-2073.
4. Boulter L, Govaere O, Bird TG, Radulescu S, Ramachandran P, Pellicoro A, Ridgway RA, Seo SS, Spee B, Van Rooijen N, et al. 2012. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med 18: 572-579.
5. Brault V, Moore R, Kutsch S, Ishibashi M, Rowitch DH, McMahon AP, Sommer L, Boussadia O, Kemler R. 2001. Inactivation of the β-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development 128: 1253-1264.
6. Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI. 2012. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle 11: 1273-1281.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
8. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M. 2011. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 71: 3863-3871.
9. Clevers H, Nusse R. 2012. Wnt/β-catenin signaling and disease. Cell 149: 1192-1205.
10. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, et al. 2012. A central role for RAF → MEK → ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2: 685-693.
11. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, et al. 2012. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23: 121-128.
12. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K. 2006. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10: 459-472.
13. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M, et al. 2011. β-Catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20: 741-754.
14. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379-384.
15. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, YouMJ, DePinho RA, McMahon M, Bosenberg M. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41: 544-552.
16. Eilers M, Picard D, Yamamoto KR, Bishop JM. 1989. Chimaeras of myc oncoprotein and steroid receptors cause hormonedependent transformation of cells. Nature 340: 66-68.
17. Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh MJ. 1998. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J Clin Invest 102: 184-193.
18. Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI. 2009. Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/ β-catenin pathway activation. Mol Cell Biol 29: 5306-5315.
19. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee R, Grippo JF, Nolop K, Chapman P. 2009. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 25: 1.
20. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, et al. 2013. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: An analysis of 1683 patients with non-small cell lung cancer. Clin Cancer Res 19: 4273-4281.
21. Haigis KM, Wistuba II, Kurie JM. 2007. Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. Genes Dev 21: 361-366.
22. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM. 1999. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J 18: 5931-5942.
23. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. 1998. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
24. Heist RS, Engelman JA. 2012. SnapShot: Non-small cell lung cancer. Cancer Cell 21: 448-448. e2.
25. Herbst RS, Heymach JV, Lippman SM. 2008. Lung cancer. N Engl J Med 359: 1367-1380.
26. Hofmann K. 2000. A superfamily of membrane-bound Oacyltransferases with implications for wnt signaling. Trends Biochem Sci 25: 111-112.
27. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248.
28. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, et al. 2007. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 67: 4933-4939.
29. Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, et al. 2013. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci 110: 12649-12654.
30. Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, Tuveson DA, Capobianco AJ, Tybulewicz VL, et al. 2007. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res 67: 8089-8094.
31. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690.
32. Lum L, Clevers H. 2012. Cell biology. The unusual case of Porcupine. Science 337: 922-923.
33. Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB, Volpin D, Bressan GM, Piccolo S. 2003. Mapping Wnt/β-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci 100: 3299-3304.
34. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM. 2004. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64: 4717-4720.
35. Mazieres J, He B, You L, Xu Z, Jablons DM. 2005. Wnt signaling in lung cancer. Cancer Lett 222: 1-10.
36. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T. 2009. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462: 104-107.
37. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA. 2013. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 3: 520-533.
38. Morrisey EE, Hogan BL. 2010. Preparing for the first breath: Genetic and cellular mechanisms in lung development. Dev Cell 18: 8-23.
39. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. 2008. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14: 447-457.
40. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, Fraire AE, Gabrielson EW, Gunning WT, Haines DC, et al. 2004. Classification of proliferative pulmonary lesions of the mouse: Recommendations of the mouse models of human cancers consortium. Cancer Res 64: 2307-2316.
41. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, et al. 2004. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11: 1192-1197.
42. Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ, Morrisey EE. 2011. Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest 121: 1935-1945.
43. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. 1992. APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237.
44. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. 2012. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103.
45. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, et al. 2008. Genetic predictors of MEK dependence in nonsmall cell lung cancer. Cancer Res 68: 9375-9383.
46. Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, Zanucco E, Castro I, Potapenko T. 2009. MYC is a metastasis gene for non-small-cell lung cancer. PLoS ONE 4: e6029.
47. Sansom OJ, Reed KR, van de Wetering M, Muncan V, Winton DJ, Clevers H, Clarke AR. 2005. Cyclin D1 is not an immediate target of β-catenin following Apc loss in the intestine. J Biol Chem 280: 28463-28467.
48. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514.
49. Sebolt-Leopold JS. 2004. MEK inhibitors: A therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 10: 1907-1914.
50. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. 2005. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 353: 123-132.
51. Siegfried E, Wilder EL, Perrimon N. 1994. Components of wingless signalling in Drosophila. Nature 367: 76-80.
52. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. 2008. Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
53. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB, Evan GI. 2013. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 27: 504-513.
54. Stewart DJ. 2014. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106: djt356.
55. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, et al. 2012. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504.
56. Tetsu O, McCormick F. 1999. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
57. Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M. 2012. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 72: 3048-3059.
58. Trejo CL, Green S, Marsh V, Collisson EA, Iezza G, Phillips WA, McMahon M. 2013. Mutationally activated PIK3CAH1047R cooperates with BRAFV600E to promote lung cancer progression. Cancer Res 73: 6448-6461.
59. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M, Sears RC. 2011. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 71: 925-936.
60. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, et al. 2012. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 72: 4765-4776.
61. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al. 2012. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505-509.
62. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, et al. 2011. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473: 101-104.
63. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. 1997. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598-5611.
64. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, et al. 2004. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23: 6170-6174.
65. Zhang Y, Goss AM, Cohen ED, Kadzik R, Lepore JJ, Muthukumaraswamy K, Yang J, DeMayo FJ, Whitsett JA, Parmacek MS, et al. 2008. A Gata6-Wnt pathway required for epithelial stem cell development and airway regeneration. Nat Genet 40: 862-870.
66. Zhu J, Woods D, McMahon M, Bishop JM. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12: 2997-3007.